Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model

Annals of the New York Academy of Sciences

Volumn 1203, Issue , 2010, Pages 7-14

  Hillegass, Jedd M ^a   Shukla, Arti ^a   Lathrop, Sherrill A ^a   MacPherson, Maximilian B ^a   Beuschel, Stacie L ^a   Butnor, Kelly J ^a   Testa, Joseph R ^b   Pass, Harvey I ^c   Carbone, Michele ^d   Steele, Chad ^e   Mossman, Brooke T ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

asbestos; chemokines; cytokines; inflammation; mesothelioma

Indexed keywords

ASBESTOS FIBER; BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; INTERLEUKIN 6; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CHRONIC INFLAMMATION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MALE; MALIGNANT MESOTHELIOMA; MOUSE; NONHUMAN; PERITONEUM LAVAGE; SCID MOUSE; TUMOR XENOGRAFT;

EID: 77956247365     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05554.x     Document Type: Conference Paper

References (38)

1. Shukla, A. et al. 2003. Multiple roles of oxidants in the pathogenesis of asbestos-induced diseases. Free Radic. Biol. Med. 34 : 1117 1129.
2. Mossman, B.T. et al. 1990. Asbestos: scientific developments and implications for public policy. Science 247 : 294 301.
3. Mossman, B.T. J.B. Gee. 1989. Asbestos-related diseases. N. Engl. J. Med. 320 : 1721 1730.
4. Robinson, B.W. R.A. Lake. 2005. Advances in malignant mesothelioma. N. Engl. J. Med. 353 : 1591 1603.
5. Pass, H.I. 2005. Mediastinal staging 2005: pictures, scopes, and scalpels. Semin. Oncol. 32 : 269 278.
6. O'Byrne, K. V. Rusch. 2006. Malignant Pleural Mesothelioma. Oxford University Press. Oxford, UK.
7. Krishnamoorthy, S. K.V. Honn. 2006. Inflammation and disease progression. Cancer Metastasis Rev. 25 : 481 491.
8. Mossman, B.T. A. Churg. 1998. Mechanisms in the pathogenesis of asbestosis and silicosis. Am. J. Respir. Crit. Care Med. 157 : 1666 1680.
9. Dostert, C. et al. 2008. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320 : 674 677.
10. Adamson, I.Y., H. Prieditis L. Young. 1997. Lung mesothelial cell and fibroblast responses to pleural and alveolar macrophage supernatants and to lavage fluids from crocidolite-exposed rats. Am. J. Respir. Cell Mol Biol. 16 : 650 656.
11. Choe, N. et al. 1997. Pleural macrophage recruitment and activation in asbestos-induced pleural injury. Environ. Health Perspect. 105 (Suppl 5 1257 1260.
12. Hill, G.D. et al. 2003. Soluble ICAM-1, MCP-1, and MIP-2 protein secretion by rat pleural mesothelial cells following exposure to amosite asbestos. Exp. Lung Res. 29 : 277 290.
13. Hillegass, J.M. et al. 2010. Utilization of gene profiling and proteomics to determine mineral pathogenicity in a human mesothelial cell line (LP9/TERT-1). J. Toxicol. Environ. Health A. 73 : 423 436.
14. Shukla, A. et al. 2009. Alterations in gene expression in human mesothelial cells correlate with mineral pathogenicity. Am. J. Respir. Cell Mol. Biol. 41 : 114 123.
15. Reale, F.R. et al. 1987. Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model. Cancer Res. 47 : 3199 3205.
16. Martarelli, D. et al. 2006. Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis. BMC Cancer 6 : 130.
17. Rdzanek, M. et al. 2006. Spindle cell tumors of the pleura: differential diagnosis. Semin. Diagn. Pathol. 23 : 44 55.
18. Gerwin, B.I. et al. 1987. Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines. Cancer Res. 47 : 6180 6184.
19. Syrokou, A. et al. 1999. Proteoglycans in human malignant mesothelioma. Stimulation of their synthesis induced by epidermal, insulin and platelet-derived growth factors involves receptors with tyrosine kinase activity. Biochimie 81 : 733 744.
20. Versnel, M.A. et al. 1988. Expression of c-sis (PDGF B-chain) and PDGF A-chain genes in ten human malignant mesothelioma cell lines derived from primary and metastatic tumors. Oncogene 2 : 601 605.
21. Strizzi, L. et al. 2001. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J. Pathol. 193 : 468 475.
22. Kumar-Singh, S. et al. 1999. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J. Pathol. 189 : 72 78.
23. Strizzi, L. et al. 2001. Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis. Int. J. Oncol. 18 : 1093 1098.
24. Kasuga, I. et al. 2001. Malignant pleural mesothelioma produces functional granulocyte-colony stimulating factor. Chest 119 : 981 983.
25. Lanfrancone, L. et al. 1992. Human peritoneal mesothelial cells produce many cytokines (granulocyte colony-stimulating factor 'CSF', granulocyte-monocyte-CSF, macrophage-CSF, interleukin-1 'IL-1', and IL-6) and are activated and stimulated to grow by IL-1. Blood 80 : 2835 2842.
26. Schmitter, D. et al. 1992. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int. J. Cancer 51 : 296 301.
27. Adachi, Y. et al. 2006. Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int. J. Cancer 119 : 1303 1311.
28. Bielefeldt-Ohmann, H. et al. 1994. Patho- and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model. Cancer Immunol. Immunother. 39 : 347 359.
29. Nakano, T. et al. 1998. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br. J. Cancer 77 : 907 912.
30. van Eeden, S.F. et al. 2005. Systemic response to ambient particulate matter: relevance to chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2 : 61 67.
31. Monti, G. et al. 1994. Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment. Cancer Res. 54 : 4419 4423.
32. Strieter, R.M. et al. 1994. The immunopathology of chemotactic cytokines: the role of interleukin-8 and monocyte chemoattractant protein-1. J. Lab. Clin. Med. 123 : 183 197.
33. Strieter, R.M. et al. 1995. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J. Leukoc. Biol. 57 : 752 762.
34. Antony, V.B. et al. 1995. Pleural mesothelial cell expression of C-C (monocyte chemotactic peptide) and C-X-C (interleukin 8) chemokines. Am. J. Respir. Cell Mol Biol. 12 : 581 588.
35. Galffy, G. et al. 1999. Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res. 59 : 367 371.
36. Galffy, G. et al. 1999. Inhibition of interleukin-8 reduces human malignant pleural mesothelioma propagation in nude mouse model. Oncol Res. 11 : 187 194.
37. Caminschi, I. et al. 1999. Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12. Am. J. Respir. Cell Mol Biol. 21 : 347 356.
38. Caminschi, I. et al. 1998. Interleukin-12 induces an effective antitumor response in malignant mesothelioma. Am. J. Respir. Cell Mol Biol. 19 : 738 746.